Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL). In this open-label, dose-escalation phase I study, dacetuzumab was administered to six cohorts of adult pat...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 27; číslo 26; s. 4371
Hlavní autoři:	Advani, Ranjana, Forero-Torres, Andres, Furman, Richard R, Rosenblatt, Joseph D, Younes, Anas, Ren, Hong, Harrop, Kate, Whiting, Nancy, Drachman, Jonathan G
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.09.2009
Témata:	Adult Aged Aged, 80 and over Anemia - chemically induced Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized CD40 Antigens - immunology Cohort Studies Cytokines - blood Dose-Response Relationship, Drug Drug Resistance, Neoplasm Fatigue - chemically induced Female Fever - chemically induced Headache - chemically induced Humans Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - metabolism Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - metabolism Male Middle Aged Recurrence Treatment Outcome Young Adult
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!